Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
bluebird bio, Inc. stock logo
BLUE
bluebird bio
$4.97
$4.78
$3.20
$25.10
$48.67M0.27450,490 shsN/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
$22.34
-1.2%
$19.01
$2.03
$14.36
$209.95M1.1150,104 shs111,114 shs
Organigram Global Inc. stock logo
OGI
Organigram Global
$1.55
+6.2%
$1.37
$0.85
$2.08
$207.61M1.36666,150 shs1.16 million shs
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
$3.43
-1.7%
$3.11
$2.58
$4.92
$228.75M159,006 shs26,351 shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
bluebird bio, Inc. stock logo
BLUE
bluebird bio
0.00%0.00%0.00%+14.52%-76.33%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
0.00%+4.25%+25.79%+85.86%-47.14%
Organigram Global Inc. stock logo
OGI
Organigram Global
+0.69%-1.35%+13.18%+37.74%-11.52%
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
-6.18%+0.87%+14.80%+19.93%-23.80%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
bluebird bio, Inc. stock logo
BLUE
bluebird bio
1.7961 of 5 stars
3.10.00.00.00.61.71.3
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Organigram Global Inc. stock logo
OGI
Organigram Global
0.5608 of 5 stars
0.01.00.00.00.60.02.5
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
2.3174 of 5 stars
3.35.00.00.01.10.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
bluebird bio, Inc. stock logo
BLUE
bluebird bio
2.25
Hold$44.60797.38% Upside
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
0.00
N/AN/AN/A
Organigram Global Inc. stock logo
OGI
Organigram Global
0.00
N/AN/AN/A
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
2.67
Moderate Buy$7.00104.08% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
bluebird bio, Inc. stock logo
BLUE
bluebird bio
$103.95M0.47N/AN/A$35.59 per share0.14
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/A$11.08 per shareN/A
Organigram Global Inc. stock logo
OGI
Organigram Global
$194.09M1.07N/AN/A$2.07 per share0.75
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
$65.17M3.51N/AN/A$1.48 per share2.32
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
bluebird bio, Inc. stock logo
BLUE
bluebird bio
-$211.91M-$41.32N/AN/AN/A-565.74%-322.46%-53.17%8/12/2025 (Estimated)
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
-$57.56M-$3.11N/AN/AN/A-37.22%-30.91%N/A
Organigram Global Inc. stock logo
OGI
Organigram Global
-$33.39M$0.1015.50N/AN/A8.05%-5.93%-4.39%8/12/2025 (Estimated)
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
-$62.49M-$1.00N/AN/AN/A-98.51%-63.47%-40.06%8/5/2025 (Estimated)

Latest BLUE, SOPH, OGI, and NLTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q1 2025
bluebird bio, Inc. stock logo
BLUE
bluebird bio
-$1.91N/AN/AN/A$45.60 millionN/A
8/12/2025Q3 2025
Organigram Global Inc. stock logo
OGI
Organigram Global
-$0.01N/AN/AN/A$68.04 millionN/A
8/5/2025Q2 2025
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
-$0.25N/AN/AN/A$17.49 millionN/A
5/6/2025Q1 2025
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
-$0.21-$0.26-$0.05-$0.26$16.76 million$17.78 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
bluebird bio, Inc. stock logo
BLUE
bluebird bio
N/AN/AN/AN/AN/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/AN/A
Organigram Global Inc. stock logo
OGI
Organigram Global
N/AN/AN/AN/AN/A
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
bluebird bio, Inc. stock logo
BLUE
bluebird bio
0.37
0.51
0.33
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/A
15.33
15.33
Organigram Global Inc. stock logo
OGI
Organigram Global
N/A
3.42
1.90
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
0.16
3.11
2.94

Institutional Ownership

CompanyInstitutional Ownership
bluebird bio, Inc. stock logo
BLUE
bluebird bio
87.43%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
52.37%
Organigram Global Inc. stock logo
OGI
Organigram Global
34.63%
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
31.59%

Insider Ownership

CompanyInsider Ownership
bluebird bio, Inc. stock logo
BLUE
bluebird bio
1.40%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
1.58%
Organigram Global Inc. stock logo
OGI
Organigram Global
0.09%
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
4.88%
CompanyEmployeesShares OutstandingFree FloatOptionable
bluebird bio, Inc. stock logo
BLUE
bluebird bio
5209.79 million9.59 millionOptionable
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
909.40 million9.25 millionNo Data
Organigram Global Inc. stock logo
OGI
Organigram Global
860133.94 million133.82 millionOptionable
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
52066.69 million63.43 millionNot Optionable

Recent News About These Companies

An end to an era: Supreme Court won't review IVF mixup ruling
M42, partners launch liquid biopsy testing in UAE
Supreme Court: IVF mixup baby to remain with birth parents
The Sophia Case: When Parenthood Isn’t Just About Genetics

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
bluebird bio stock logo

bluebird bio NASDAQ:BLUE

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

Neoleukin Therapeutics stock logo

Neoleukin Therapeutics NASDAQ:NLTX

$22.34 -0.26 (-1.15%)
As of 07/18/2025

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Organigram Global stock logo

Organigram Global NASDAQ:OGI

$1.55 +0.09 (+6.16%)
Closing price 04:00 PM Eastern
Extended Trading
$1.56 +0.01 (+0.97%)
As of 05:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.

SOPHiA GENETICS stock logo

SOPHiA GENETICS NASDAQ:SOPH

$3.43 -0.06 (-1.72%)
Closing price 04:00 PM Eastern
Extended Trading
$3.42 -0.02 (-0.44%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.